All News

The prevalence of major depressive disorder (MDD) grew from a rate of 6.4% in 2005 to 6.8% in 2010 with the cost of MDD to employers increasing 21.5% over the same time period, according to a new study in the Journal of Clinical Psychiatry.

Contributions from employers and workers to health savings accounts were on the decline in 2014, according to new research from the Employee Benefit Research Institute.

Although those opposing the Affordable Care Act have decried the burdensome nature of the individual mandate, a recent proposal developed by Republicans seeks to address the same problem as the ACA's mandate and would impose strong penalties on the uninsured.

Several high-profile disputes between health systems and insurers made headlines in recent months, with some of those disagreements leading to contracts expiring without a new one in place.

A 2011 switch to Medicaid managed care, which occurred during a budget crisis, has been blamed for financial challenges at rural hospitals and declining numbers of providers. Auditor Adam Edelen said the plight of Kentucky's rural hospitals is complex but must be addressed.

Researchers at Dartmouth's Norris Cotton Cancer Center designed rehabilitation intervention to help women with breast cancer find ways to accelerate recovery and engage in health-promoting activities.

Senator Robert Menendez is accused of using his position to help a Florida doctor who split vials of the eye drug Lucentis and then billed Medicare for multiple treatments.

With a focus on improving quality while maintaining the cost of care, providers and payers are evaluating various payment models that could improve patient outcomes using evidence-based treatment at lower costs to the healthcare system.

The Robert Wood Johnson Foundation's advisory committee for the Data for Health initiative released its first report with insights, concerns, and ideas from the public about how to harness data to improve health.

While supporting the FDA's standards-based regulatory efforts to explore next generation sequencing tests as diagnostic tools, the American Society of Clinical Oncology warned against misinterpretation or over-interpretation of test results.

Research published by a team of Italian scientists in the Journal of the National Institute of Cancer shows that a 13-gene panel blood test for microRNAs could be a cost-effective screening tool for lung cancer, compared with low-dose CT, which is expensive.

States that decide to carve out their pharmacy benefits from Medicaid plans have significantly higher costs, according to a report requested by America's Health Insurance Plans from The Menges Group.

With an aim to grab band-width in the shared PD-1 space, Merck has partnered with Syntax to conduct combination studies of Keytruda with Entinostat in melanoma and lung cancer patients.

Aggressive policies that target the use and promotion of off-label use are needed to prevent the use of drugs for non-approved indications with little benefit or with harmful outcomes.

The annual report was published in the March 30 issue of the Journal of the National Cancer Institute. The report was co-authored by experts from the North American Association of Central Cancer Registries, the American Cancer Society, CDC, and the National Cancer Institute.

The "Know Your Tumor" initiative of the Pancreatic Cancer Action network refers newly diagnosed patients to Perthera, which provides a unique service to ensure timely tissue collection, molecular diagnostic testing, and a report with recommendations for the oncologist.

Physicians were accepting nearly equal amounts of new Medicare and privately insured patients in 2013, but much fewer were accepting new Medicaid patients, according to a new report from the CDC's National Center for Health Statistics.

Knowledge is power, as was the case with a doctoral student at MIT whose keen interest in his own medical data resulted in the diagnosis and excision of a brain tumor. But are all health systems ready to share patients' data with them?

Although healthcare stakeholders view comparative effectiveness research (CER) as important to healthcare, respondents to a survey from the National Pharmaceutical Council admitted that they haven't yet seen the impact of CER.

The battle is being closely watched for signs that brand-name drug makers may be able to delay the introduction of biosimilars, which are cheaper versions of brand-name biologics.

Hospitals like Boston Children's and Penn Medicine think they are better off building in-house apps that are custom-made for their workflow, rather than risk buying those available in the market, which may not necessarily be a perfect fit.

An excisional biopsy, which is common in case a breast lump is detected, involves an incision along the contour of the breast and removeing the lump. However, this procedure can result in pain, scarring and breast deformity.

The Supreme Court of the United States ruled on Tuesday that providers cannot sue states over low Medicaid reimbursement rates, overturning the decision of the lower court.

Long before patient-centered care and value-based models were the order of the day, Geisinger was focused on delivery care that was not focused on figuring out who would pay the bill.

The Affordable Care Act's insurance exchanges leave much to be desired with regard to transparency when patients are shopping for health coverage, according to a survey from the National Health Council.

Researchers worked with nearly 3800 individuals to establish workplace programs that focused on healthy eating and increasing physical activity. At the end of the study period, the number of employees in the control site who were overweight/obese increased by about 5%, while the number in the intervention group had decreased by 4%, resulting in a net difference of 9%.

Low pre-surgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer is associated with increased overall survival and a longer time before tumor recurrence, a study shows. Patients with high labeled glucose uptake may benefit from additional therapy following surgery.

Studies presented at the annual meting of the Society of Gynecologic Oncology, in Chicago, evaluated the efficacy of an experimental vaccine and an angiogenesis inhibitor in preventing the recurrence of ovarian cancer.

With a combined 1 billion scripts annually, UnitedHealth will be about the same size as current industry number 2, CVS Health Corp.

A new study published by the IMS Institute for Healthcare Informatics finds that reimbursement approaches based on cost-per-quality-adjusted-life-year measures rather than drug effectiveness may limit access to innovative cancer treatments.